Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2023 | Highlights in melanoma at AACR 2023

Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, shares his highlights in melanoma from AACR 2023. The Phase II KEYNOTE-942 (NCT03897881) clinical trial explored adjuvant treatment with the personalized cancer vaccine mRNA-4157 and pembrolizumab in participants with high-risk melanoma, demonstrating a reduced the likelihood of melanoma recurring or causing death by 44% when compared to pembrolizumab alone. The Phase I/II trial MK-3475-02C/KEYMAKER-U02 (NCT04303169) investigated neoadjuvant vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with stage IIIB-D melanoma, showing numerically higher objective response, event-free survival (EFS), and recurrence-free survival (RFS) rates. Both Phase II studies are now launching into Phase III, holding the potential to eventually impact standard of care. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.